Home › Research › Treatments
Biomarcadores de laboratorio en la enfermedad de Alzheimer: avances recientes e implantación en un hospital de tercer nivel
Antonio León‐Justel, Félix Sánchez-Fernández, Félix Viñuela-Fernández, Fernando F. Ortega-Ortega, Israel Olivas-Martínez, Jose M. López-Domínguez, Paloma Menéndez-Valladares, Rafael Pérez-Noguera. Kranion, 2025-08-22
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
ResumenLa enfermedad de Alzheimer (EA) es una enfermedad neurodegenerativa crónica que se caracteriza por la acumulación excesiva de proteína beta-amiloide y de proteína Tau fosforilada.Es una enfermedad multifactorial asociada con múltiples factores de riesgo, incluyendo el envejecimiento.Presenta varias etapas: fase preclínica asintomática, deterioro cognitivo leve y demencia.Actualmente se emplean para el diagnóstico biomarcadores en líquido cefalorraquídeo (LCR): proteína amiloide Aβ42, ratio Aβ42/Aβ40, proteína Tau total (t-Tau), y proteína Tau fosforilada (p-Tau181).El diagnóstico se basa en la clasificación biológica de la enfermedad, mediante el sistema AT(N)I: A, depósitos de Aβ-Aβ (PET amiloide, proteínas en LCR [Aβ42 y ratio Aβ42/Aβ40]); T, Tau PET y LCR p-Tau; N, pruebas de imagen y LCR t-Tau, neurofilamentos de cadena ligera (NfL); I, inflamación, proteína ácida fibrilar glial (GFAP).La proteína p-Tau217 en plasma es uno de los biomarcadores emergentes más prometedores en la EA.La variante plasmática de p-Tau es la que mejor concordancia presenta entre plataformas.En la actualidad, la EA no tiene cura.La FDA ha aprobado recientemente dos fármacos, donanemab y lecanemab, que han demostrado su eficacia en la eliminación de la placa Aβ y en la ralentización del deterioro cognitivo, pero no están exentos de efectos secundarios.
What this study adds
Evidence grade: Low
This review describes how cerebrospinal fluid biomarkers (Aβ42, the Aβ42/Aβ40 ratio, t-Tau, p-Tau181) and the AT(N)I classification are used to diagnose Alzheimer's disease, with plasma p-Tau217 described as one of the most promising emerging biomarkers. It states that Alzheimer's currently has no cure, and that the FDA recently approved donanemab and lecanemab, which remove amyloid plaque and slow cognitive decline but are not free of side effects.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
León‐Justel, A., Sánchez-Fernández, F., Viñuela-Fernández, F., Ortega-Ortega, F. F., Olivas-Martínez, I., López-Domínguez, J. M., et al. (2025). Biomarcadores de laboratorio en la enfermedad de Alzheimer: avances recientes e implantación en un hospital de tercer nivel. Kranion. https://doi.org/10.24875/kranion.m25000107
Vancouver
León‐Justel A, Sánchez-Fernández F, Viñuela-Fernández F, Ortega-Ortega FF, Olivas-Martínez I, López-Domínguez JM, et al. Biomarcadores de laboratorio en la enfermedad de Alzheimer: avances recientes e implantación en un hospital de tercer nivel. Kranion. 2025. doi:10.24875/kranion.m25000107.
BibTeX
@article{leonjustel2025-520c3a35,
author = {León‐Justel, Antonio and Sánchez-Fernández, Félix and Viñuela-Fernández, Félix and Ortega-Ortega, Fernando F. and Olivas-Martínez, Israel and López-Domínguez, Jose M. and Menéndez-Valladares, Paloma and Pérez-Noguera, Rafael},
title = {{Biomarcadores de laboratorio en la enfermedad de Alzheimer: avances recientes e implantación en un hospital de tercer nivel}},
journal = {Kranion},
year = {2025},
doi = {10.24875/kranion.m25000107},
url = {https://doi.org/10.24875/kranion.m25000107}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- ResumenLa enfermedad de Alzheimer (EA) es una enfermedad neurodegenerativa crónica que se caracteriza por la acumulación excesiva de proteína beta-amiloide y de proteína Tau fosforilada.Es una enfermedad multifactorial asociada con múltiples factores de riesgo, incluyendo el envejecimiento.Presenta
Why it matters
This review describes how cerebrospinal fluid biomarkers (Aβ42, the Aβ42/Aβ40 ratio, t-Tau, p-Tau181) and the AT(N)I classification are used to diagnose Alzheimer's disease, with plasma p-Tau217 described as one of the most promising emerging biomarkers. It states that Alzheimer's currently has no cure, and that the FDA recently approved donanemab and lecanemab, which remove amyloid plaque and slow cognitive decline but are not free of side effects.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 26/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 25 of the 96 points we could judge it on, which is 26 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Kranion) |
| Journal's citation record | 0 / 4 | Kranion: journal h-index 2 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Rafael Pérez-Noguera holds only 1 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | Hospital Universitario Virgen Macarena: institution h-index 271 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 25 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 25 of the 96 points we could judge it on is 26 out of 100. |
| Total | 26 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also in Treatments
203 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.